Abeona Therapeutics Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Cleveland, OH. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $6 million and a profit of $71 million (its filed statements).
Pre-revenue companyPharmaceutical PreparationsCleveland, OHfilings since 19958 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 2834), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 5.4 out of ten, 8 of 9 metrics filed and 1 estimated: past 3.9 out of ten, present 5.5 out of ten, future 6.3 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 4.1 out of ten. 6 warning events since 2017; the latest 2023-10-18. 41st percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 5.6 out of ten. +27.4% a year over 7 filed years; profitable in 1 of 9. 56th percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 1.4 out of ten. CrossAssetData estimate 1.4/10, confidence 35 of 100 (one part). 14th percentile among 463 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 5.3 out of ten. ROE 45%: 45¢ of profit per shareholder dollar. Leverage 27%: owes 27¢ per asset dollar. 53rd percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 6.5 out of ten. top 35% of 314 in its family; net margin 1223.1%. 65th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 5.0 out of ten. top 50% of 315 in its family for leadership; chief executive since 2021. 50th percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 4.9 out of ten. bottom 49% of 272 in its family for room to expand. 49th percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 6.1 out of ten. top 39% of 307 in its family for growth drivers. 61st percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 8.8 out of ten. top 12% of 234 in its family for expectations against reality. 88th percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-03-17 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-13 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-13 (on EDGAR). Newest filing: Form 144, 2026-09-29. Filings on record since 1995. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: License 58%, Product 42%. As tagged in its annual report (Form 10-K, filed 2026-03-17).
Who runs it
Seshadri, Vishwas (Chief Executive Officer); Amoroso, Michael (Chief Executive Officer); Vazzano, Joseph Walter (Chief Financial Officer); Silverstein, Christine Berni (Chief Financial Officer); O'Malley, Brendan M. (SVP, Chief Legal Officer); Vasanthavada, Madhav (Chief Commercial Officer); Alvino, Mark (director); Alland, Leila (director); Crombez, Eric (director); Goldan, Keith A. (director); and 3 more. 13 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.